Contributor License Agreement

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

Retrieved on: 
Friday, November 17, 2023

HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.

Key Points: 
  • HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.
  • “We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities,” stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics.
  • “The license agreement represents an important milestone for Serina.”

Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)

Retrieved on: 
Thursday, December 14, 2023

SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients that are not amenable to surgery.

Key Points: 
  • SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients that are not amenable to surgery.
  • Previously, pimicotinib was granted the breakthrough therapy designation ("BTD") by the U.S. FDA for TGCT in January, 2023.
  • Fast Track is a policy designed to facilitate the development and expedite the review of drugs in order to treat serious conditions and fulfill unmet medical needs.
  • Pimicotinib is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor, independently developed by Abbisko Therapeutics.

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

Retrieved on: 
Monday, December 4, 2023

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.

Key Points: 
  • SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.
  • Abbisko Therapeutics has also granted Merck an exclusive option for global commercial rights of pimicotinib, subject to the terms and conditions as agreed between the parties (the "Global Commercialization Option").
  • Pursuant to the License Agreement, Abbisko Therapeutics will receive a one-time, non-refundable down payment of US$ 70 million.
  • In the event that Merck exercises the Global Commercialization Option, Merck will pay Abbisko Therapeutics an additional option exercise fee.

Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia

Retrieved on: 
Wednesday, March 29, 2023

SHANGHAI, China and SINGAPORE, March 28, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Rxilient Biotech announced the collaboration on the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam. This collaboration is another significant milestone in toripalimab’s journey abroad. So far, toripalimab has been involved in overseas business activities in over 30 countries, spanning across North America, the Middle East, North Africa and South East Asia.

Key Points: 
  • So far, toripalimab has been involved in overseas business activities in over 30 countries, spanning across North America, the Middle East, North Africa and South East Asia.
  • “This extensive collaboration with Rxilient Biotech in Southeast Asia is a vital step for Junshi Biosciences as we strive to expand our global commercialization network,” said Dr. Ning LI, CEO of Junshi Biosciences.
  • Based in Singapore, it will radiate to Southeast Asia and thereafter the other global market, and strive to build a bridgehead for global Biotech and pharmaceutical companies in Southeast Asia.
  • Upon completion of the issuance, Rxilient Biotech and Junshi Biosciences will own 60% and 40% of Excellmab, respectively.

Curio Wellness Announces Exclusive Brand Licensing Agreements with Smokiez

Retrieved on: 
Tuesday, January 24, 2023

TOWSON, Md., Jan. 24, 2023 /PRNewswire-PRWeb/-- Curio Wellness, a cGMP-certified, vertically integrated medical cannabis company and market-leading innovator of health and wellness products derived from cannabis, today announced an exclusive brand licensing agreement with Smokiez. Through this exclusive partnership, the Curio team will bring Smokiez's suite of products, voted Colorado's "Best Edibles" by High Times, to Maryland.

Key Points: 
  • TOWSON, Md., Jan. 24, 2023 /PRNewswire-PRWeb/-- Curio Wellness , a cGMP-certified, vertically integrated medical cannabis company and market-leading innovator of health and wellness products derived from cannabis, today announced an exclusive brand licensing agreement with Smokiez.
  • Through this exclusive partnership, the Curio team will bring Smokiez's suite of products, voted Colorado's "Best Edibles" by High Times, to Maryland.
  • "Our cGMP certification opens the door to opportunities with premium brands across the country, and we're focused on continuing to bring high quality products to the state of Maryland that complement the Curio Wellness Brand."
  • Curio Wellness will manufacture the Smokiez line of products in its cGMP-certified facility in Hunt Valley, MD.

PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals

Retrieved on: 
Thursday, January 12, 2023

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ("Endosane"), a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel technology for the delivery of cannabinoid products on an exclusive basis (the "Option Agreement").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ("Endosane"), a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel technology for the delivery of cannabinoid products on an exclusive basis (the "Option Agreement").
  • The purpose of the Option Agreement is for Endosane to evaluate the bioavailability of cannabinoids with the sol-gel technology.
  • Stephen Van Deventer, CEO and Chairman of PreveCeutical, commented, "We are confident that the agreement with Endosane will help facilitate our path to commercialization and revenues.
  • If the option to license the Sol-Gel technology is exercised, in consideration of the rights granted, the License Agreement is expected to contain certain milestones, as listed below, which will require payments to be made by Endosane to PreveCeutical when each milestone is met and approved.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem(meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaboremin China and bring better treatment options to patients with severe ailments.

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Retrieved on: 
Tuesday, September 20, 2022

Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).

Key Points: 
  • Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China).
  • This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE).
  • According to China Antimicrobial Surveillance Network (CHINET), theincidence ofcarbapenem-resistantKlebsiella pneumoniae (CRKP) infections has experienced a steep increase in the last 10 years.
  • "We are excited to partner with Menarini to develop and commercialize Vaborem in China and bring better treatment options to patients with severe ailments.

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Retrieved on: 
Thursday, October 21, 2021

Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.

Key Points: 
  • Under the terms of the agreement, Emergence Therapeutics will use a PSARlink drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.
  • This technology has the potential to widen the therapeutic index of an ADC and to make our Nectin-4 ADC a best-in-class.
  • Pursuant to the agreement, Mablink Bioscience is entitled to receive milestone and royalty payments, based on the development of the Nectin-4 ADC.
  • Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers.

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Retrieved on: 
Wednesday, October 20, 2021

NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.

Key Points: 
  • NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.
  • Regarding pulmonary edema, MLR-1023 is clearly differentiated from commonly used therapeutics today, including anti-inflammatory drugs and vaccines.
  • Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.Meliorpharmaceuticals.com .